Levee Medical Highlights Progress in ARID II Pivotal Trial Enrollment

According to a recent LinkedIn post from Levee Medical, Academic Urology and Urogynecology of Arizona has enrolled its first patient in the ARID II IDE pivotal trial, becoming the 16th site to do so. The post indicates that the trial is focused on evaluating the Voro® Urologic Scaffold and its impact on early and long-term continence outcomes following prostate surgery.

The post suggests ongoing progress in building the pivotal trial dataset, which may be a key step toward generating the clinical evidence needed for potential regulatory review and future commercialization. For investors, continued site activation and enrollment momentum could signal advancing clinical execution and help clarify Levee Medical’s prospects in the post-prostatectomy care market.